Cancer Drug Prices Grow Post-Launch And Surge With sNDA Approval, Study Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement should be pegged to indication-specific value, a study of oral cancer drug pricing in Health Affairs concludes.